Search

Your search keyword '"Althouse, Sandra"' showing total 363 results
Start Over Author "Althouse, Sandra"
363 results on '"Althouse, Sandra"'

8. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Author

Sanchez, Victoria A., primary, Dinh, Paul C., additional, Monahan, Patrick O., additional, Althouse, Sandra, additional, Rooker, Jennessa, additional, Sesso, Howard D., additional, Dolan, M. Eileen, additional, Weinzerl, Mandy, additional, Feldman, Darren R., additional, Fung, Chunkit, additional, Einhorn, Lawrence H., additional, Frisina, Robert D., additional, and Travis, Lois B., additional

Published
2024
Full Text
View/download PDF

19. High‐dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience.

Author

Richardson, Noah H., Taza, Fadi, Abonour, Rafat, Althouse, Sandra K., Ashkar, Ryan, Abu Zaid, Mohammad, Hanna, Nassar H., Kesler, Kenneth A., Adra, Nabil, and Einhorn, Lawrence H.

Subjects
SALVAGE therapy, OVERALL survival, SURVIVAL rate, BLOOD cells, COMBINATION drug therapy, STEM cell transplantation, GERM cell tumors
Abstract

Background: Patients with relapsed primary mediastinal nonseminomatous germ cell tumor have low cure rates with salvage chemotherapy or surgery. The authors report survival outcomes of patients who received high‐dose chemotherapy (HDCT) and peripheral blood stem cell transplantation (PBSCT) at Indiana University. Methods: The prospectively maintained Indiana University germ cell tumor database identified 32 patients with primary mediastinal nonseminomatous germ cell tumor who progressed after first‐line cisplatin‐based combination chemotherapy and received HDCT and PBSCT between 2006 and 2021. Therapy included two consecutive courses of HDCT consisting of 700 mg/m2 carboplatin and 750 mg/m2 etoposide, each for 3 consecutive days, and each followed by PBSCT. A second course was not given if the patient experienced progressive disease or prohibitive toxicity. Progression‐free survival and overall survival were analyzed using the Kaplan–Meier method. Medians with 95% confidence intervals were also calculated along with 2‐year probabilities. Results: The median age at HDCT was 30 years (range, 18–61 years). With a median follow‐up of 4.7 years (range, 1–14 years), the 2‐year progression‐free survival rate was 31% (95% confidence interval, 16%–47%), and the 2‐year overall survival rate was 35% (95% confidence interval, 19%–52%). At last follow‐up, nine patients (28%) remained without evidence of disease, including two platinum‐refractory patients and two patients who were receiving HDCT as third‐line therapy. There were three treatment‐related deaths. Conclusions: Salvage HDCT and PBSCT is an active combination in patients who have relapsed primary mediastinal nonseminomatous germ cell tumor with curative potential and prolonged survival, including in platinum‐refractory and third‐line settings. The authors recommend this approach for initial salvage chemotherapy in this patient population. Patients who have relapsed primary mediastinal nonseminomatous germ cell tumors have poor outcomes with salvage chemotherapy. The authors report the results of high‐dose chemotherapy and peripheral blood stem cell transplantation, which permit more rapid succession to the subsequent cycle and potentially improved efficacy compared with historical regimens. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Data from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Author

Khatpe, Aditi S., primary, Dirks, Rebecca, primary, Bhat-Nakshatri, Poornima, primary, Mang, Henry, primary, Batic, Katie, primary, Swiezy, Sarah, primary, Olson, Jacob, primary, Rao, Xi, primary, Wang, Yue, primary, Tanaka, Hiromi, primary, Liu, Sheng, primary, Wan, Jun, primary, Chen, Duojiao, primary, Liu, Yunlong, primary, Fang, Fang, primary, Althouse, Sandra, primary, Hulsey, Emily, primary, Granatir, Maggie M., primary, Addison, Rebekah, primary, Temm, Constance J., primary, Sandusky, George, primary, Lee-Gosselin, Audrey, primary, Nephew, Kenneth, primary, Miller, Kathy D., primary, and Nakshatri, Harikrishna, primary

Published
2023
Full Text
View/download PDF

39. Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Author

Khatpe, Aditi S., primary, Dirks, Rebecca, primary, Bhat-Nakshatri, Poornima, primary, Mang, Henry, primary, Batic, Katie, primary, Swiezy, Sarah, primary, Olson, Jacob, primary, Rao, Xi, primary, Wang, Yue, primary, Tanaka, Hiromi, primary, Liu, Sheng, primary, Wan, Jun, primary, Chen, Duojiao, primary, Liu, Yunlong, primary, Fang, Fang, primary, Althouse, Sandra, primary, Hulsey, Emily, primary, Granatir, Maggie M., primary, Addison, Rebekah, primary, Temm, Constance J., primary, Sandusky, George, primary, Lee-Gosselin, Audrey, primary, Nephew, Kenneth, primary, Miller, Kathy D., primary, and Nakshatri, Harikrishna, primary

Published
2023
Full Text
View/download PDF

40. TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Author

Khatpe, Aditi S., primary, Dirks, Rebecca, additional, Bhat-Nakshatri, Poornima, additional, Mang, Henry, additional, Batic, Katie, additional, Swiezy, Sarah, additional, Olson, Jacob, additional, Rao, Xi, additional, Wang, Yue, additional, Tanaka, Hiromi, additional, Liu, Sheng, additional, Wan, Jun, additional, Chen, Duojiao, additional, Liu, Yunlong, additional, Fang, Fang, additional, Althouse, Sandra, additional, Hulsey, Emily, additional, Granatir, Maggie M., additional, Addison, Rebekah, additional, Temm, Constance J., additional, Sandusky, George, additional, Lee-Gosselin, Audrey, additional, Nephew, Kenneth, additional, Miller, Kathy D., additional, and Nakshatri, Harikrishna, additional

Published
2023
Full Text
View/download PDF

41. Supplementary Data from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Author

Khatpe, Aditi S., primary, Dirks, Rebecca, primary, Bhat-Nakshatri, Poornima, primary, Mang, Henry, primary, Batic, Katie, primary, Swiezy, Sarah, primary, Olson, Jacob, primary, Rao, Xi, primary, Wang, Yue, primary, Tanaka, Hiromi, primary, Liu, Sheng, primary, Wan, Jun, primary, Chen, Duojiao, primary, Liu, Yunlong, primary, Fang, Fang, primary, Althouse, Sandra, primary, Hulsey, Emily, primary, Granatir, Maggie M., primary, Addison, Rebekah, primary, Temm, Constance J., primary, Sandusky, George, primary, Lee-Gosselin, Audrey, primary, Nephew, Kenneth, primary, Miller, Kathy D., primary, and Nakshatri, Harikrishna, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Author

Radovich, Milan, primary, Solzak, Jeffrey P., primary, Wang, Chao J., primary, Hancock, Bradley A., primary, Badve, Sunil, primary, Althouse, Sandra K., primary, Bray, Steven M., primary, Storniolo, Anna Maria V., primary, Ballinger, Tarah J., primary, Schneider, Bryan P., primary, and Miller, Kathy D., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Author

Radovich, Milan, primary, Solzak, Jeffrey P., primary, Wang, Chao J., primary, Hancock, Bradley A., primary, Badve, Sunil, primary, Althouse, Sandra K., primary, Bray, Steven M., primary, Storniolo, Anna Maria V., primary, Ballinger, Tarah J., primary, Schneider, Bryan P., primary, and Miller, Kathy D., primary

Published
2023
Full Text
View/download PDF

44. Data from Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Author

Radovich, Milan, primary, Solzak, Jeffrey P., primary, Wang, Chao J., primary, Hancock, Bradley A., primary, Badve, Sunil, primary, Althouse, Sandra K., primary, Bray, Steven M., primary, Storniolo, Anna Maria V., primary, Ballinger, Tarah J., primary, Schneider, Bryan P., primary, and Miller, Kathy D., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figures S1-S6 from Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor

Author

Sahu, Ravi P., primary, Ocana, Jesus A., primary, Harrison, Kathleen A., primary, Ferracini, Matheus, primary, Touloukian, Christopher E., primary, Al-Hassani, Mohammed, primary, Sun, Louis, primary, Loesch, Mathew, primary, Murphy, Robert C., primary, Althouse, Sandra K., primary, Perkins, Susan M., primary, Speicher, Paul J., primary, Tyler, Douglas S., primary, Konger, Raymond L., primary, and Travers, Jeffrey B., primary

Published
2023
Full Text
View/download PDF

46. Data from Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor

Author

Sahu, Ravi P., primary, Ocana, Jesus A., primary, Harrison, Kathleen A., primary, Ferracini, Matheus, primary, Touloukian, Christopher E., primary, Al-Hassani, Mohammed, primary, Sun, Louis, primary, Loesch, Mathew, primary, Murphy, Robert C., primary, Althouse, Sandra K., primary, Perkins, Susan M., primary, Speicher, Paul J., primary, Tyler, Douglas S., primary, Konger, Raymond L., primary, and Travers, Jeffrey B., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Methods from Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor

Author

Sahu, Ravi P., primary, Ocana, Jesus A., primary, Harrison, Kathleen A., primary, Ferracini, Matheus, primary, Touloukian, Christopher E., primary, Al-Hassani, Mohammed, primary, Sun, Louis, primary, Loesch, Mathew, primary, Murphy, Robert C., primary, Althouse, Sandra K., primary, Perkins, Susan M., primary, Speicher, Paul J., primary, Tyler, Douglas S., primary, Konger, Raymond L., primary, and Travers, Jeffrey B., primary

Published
2023
Full Text
View/download PDF

48. Table Supplementary S-I from Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor

Author

Sahu, Ravi P., primary, Ocana, Jesus A., primary, Harrison, Kathleen A., primary, Ferracini, Matheus, primary, Touloukian, Christopher E., primary, Al-Hassani, Mohammed, primary, Sun, Louis, primary, Loesch, Mathew, primary, Murphy, Robert C., primary, Althouse, Sandra K., primary, Perkins, Susan M., primary, Speicher, Paul J., primary, Tyler, Douglas S., primary, Konger, Raymond L., primary, and Travers, Jeffrey B., primary

Published
2023
Full Text
View/download PDF

49. Abstract P2-26-08: Influence of genetic ancestry on breast stromal cells provides biologic basis for increased incidence of metaplastic breast cancer in women of African descent

Author

Kumar, Brijesh, primary, Batic, Katie, additional, Bhat-Nakshatri, Poornima, additional, Granatir, Maggie, additional, Addison, Rebekah, additional, Szymanski, Megan, additional, Baldridge, Lee Ann, additional, Temm, Constance, additional, Sandusky, George, additional, Althouse, Sandra, additional, Storniolo, Anna Maria, additional, and Nakshatri, Harikrishna, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results